A5066747330- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Immunotherapy and Immune Responses
- COVID-19 Impact on Reproduction
- Animal Virus Infections Studies
- Tryptophan and brain disorders
- Pharmacological Receptor Mechanisms and Effects
- Virology and Viral Diseases
- Infection Control and Ventilation
- Viral gastroenteritis research and epidemiology
- COVID-19 epidemiological studies
- vaccines and immunoinformatics approaches
- Vitamin C and Antioxidants Research
- Herpesvirus Infections and Treatments
University of Duisburg-Essen
2020-2024
Essen University Hospital
2022-2024
Public Health Agency of Canada
2024
Tianjin Medical University General Hospital
2024
Queen Mary University of London
2024
Institute of Bioorganic Chemistry
2024
Sri Sathya Sai Institute of Higher Learning
2024
University of Leeds
2024
Loyola University Chicago
2024
Background: Immune responses following vaccination against COVID-19 with different vaccines and the waning of immunity vary within population. Genetic host factors are likely to contribute this variability. However, best our knowledge, no study on G protein polymorphisms has been published so far. Methods: Antibodies SARS-CoV-2 spike T-cell a peptide pool S1 proteins were measured 1 6 months after second mRNA-1273 in main group 204 participants. Additionally, antibodies 597 participants...
Abstract We investigated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among a group of convalescent, potential blood donors in Germany who had PCR-confirmed SARS-CoV-2 infection. Sixty days after onset symptoms, 13/78 (17%) study participants borderline or negative results to an ELISA detecting IgG the S1 protein SARS-CoV-2. analyzed with infection strong antibody (ratio >3) as positive controls and without symptoms household contact infected patients...
Abstract We investigated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among a group of convalescent, potential blood donors in Germany who had PCR-confirmed SARS-CoV-2 infection. Sixty days after onset symptoms, 13/78 (17%) study participants borderline or negative results to an ELISA detecting IgG the S1 protein SARS-CoV-2. analyzed with infection strong antibody (ratio >3) as positive controls and without symptoms household contact infected patients...
The cellular response to SARS-CoV-2 vaccination and infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients is not yet clear. In the current study, HSCT prior post were tested for SARS-CoV-2-specific humoral immunity. Antibodies against spike (S) 1 assessed by Anti-SARS-CoV-2 IgG ELISA (Euroimmun). Cellular immunity was analyzed an house interferon-gamma ELISpot T-SPOT.COVID (Oxford Immunotec), using altogether seven antigens. 117 patients vaccinated twice, antibodies...
Background Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are increasingly observed in vaccinated individuals. Immune responses towards SARS-CoV-2 variants, particularly Omicron-BA.5, poorly understood. We investigated the humoral and cellular immune of hospitalized COVID-19 patients during Delta Omicron infection waves. Methods The corresponding variant respective were identified by whole genome sequencing. Humoral analyzed ELISA a cell...
The novel, highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered a pandemic of illness worldwide and remains huge threat to the healthcare system's capacity respond COVID-19. Elderly immunocompromised patients are at increased risk for course These high-risk groups have been identified as developing diminished humoral cellular immune responses. Notably, SARS-CoV-2 RNA detectable in nasopharyngeal swabs these prolonged period time. factors complicate...
In kidney transplant (KTX) patients, immune responses after booster vaccination against SARS-CoV-2 are inadequately examined. We analyzed these patients a median of four months third/fourth and compared them to healthy controls. Cellular were by interferon-gamma (IFN-γ) interleukin-2 (IL-2) ELISpot assays. Neutralizing antibody titers assessed D614G (wild type) the variants alpha, delta, omicron cell culture-based neutralization assay. Humoral immunity was also determined competitive...
Vulnerable patients such as immunosuppressed or elderly are at high risk for a severe course of COVID-19 upon SARS-CoV-2 infection. Immunotherapy with specific monoclonal antibodies (mAb) convalescent plasma represents considerable treatment option to protect these from lethal However, not always available less effective against emerging variants. Convalescent is more commonly and may represent good alternative in low-income countries. We retrospectively evaluated outcomes individuals...
While SARS-CoV-2 has transitioned to an endemic phase, infections caused by newly emerged variants continue result in severe, and sometimes fatal, outcomes or lead long-term COVID-19 symptoms. Vulnerable populations, such as PLWH, face elevated risk of severe illness. Emerging SARS-CoV-2, including numerous Omicron subvariants, are increasingly associated with breakthrough infections. Adapting mRNA vaccines these new may offer improved protection against for vulnerable individuals. In this...
When patients with chronic kidney disease are infected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) they can face two specific problems: virus-specific immune responses may be impaired and remdesivir, an antiviral drug described to shorten recovery, is contraindicated. Antiviral treatment convalescent plasma (CP) could alternative option. In this case report, we present transplant recipients hemodialysis who were SARS-CoV-2 received CP. Antibodies against the receptor-binding...
The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome 2 (SARS-CoV-2) is currently greatest medical challenge. Although crucial to future management of pandemic, factors affecting persistence long-term SARS-CoV-2 immunity are not well understood. Therefore, we determined extent important correlates specific protection in 200 unvaccinated convalescents after COVID-19. To investigate effective memory response against virus, T cell and humoral (including...
Protecting vulnerable groups from severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection is mandatory. Immune responses after a third vaccination against SARS-CoV-2 are insufficiently studied in patients hematopoietic stem-cell transplantation (HSCT). We analyzed immune before and HSCT healthy controls. Cellular immunity was assessed using interferon-gamma (IFN-γ) interleukin-2 (IL-2) ELISpots. Furthermore, this the first report on neutralizing antibodies 11 variants of...
Background and aims: Albeit several factors which influence the outcome of corona virus disease (COVID-19) are already known, genetic markers may predict in hospitalized patients still very sparse. Thus, this study, we aimed to analyze whether single-nucleotide polymorphism (SNP) rs5443 gene GNB3 , was associated with higher T cell responses previous studies, might be a suitable biomarker COVID-19 comprehensive German cohort. Methods: We analyzed demographics, pre-existing disorders,...
The pandemic caused by SARS-CoV-2 is still a major health problem. Newly emerging variants and long-COVID-19 represent challenge for the global system. In particular, individuals in developing countries with insufficient care need easily accessible, affordable effective treatments of COVID-19. Previous studies have demonstrated efficacy functional inhibitors acid sphingomyelinase against infections various viruses, including early SARS-CoV-2. This work investigated whether fluoxetine...
The pandemic caused by SARS-CoV-2 is still a major health problem. Newly emerging variants and long-COVID-19 represent challenge for the global system. In particular, individuals in developing countries with insufficient care need easily accessible, affordable effective treatments of COVID-19. Previous studies have demonstrated efficacy functional inhibitors acid sphingomyelinase (FIASMA) against infections various viruses, including early SARS-CoV-2. This work investigated whether...
Herd immunity is essential to control severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), especially in immunocompromised patients. Convalescent individuals should be vaccinated later due vaccine shortage, as studies show that neutralizing antibodies generated during infection are stable for at least 6 months. Cellular also detectable However, there evidence of cross-reactivity T cells with human endemic coronaviruses (HCoVs). Here, we cross-reactivity—which may prevent the...
Immunocompromised patients are at increased risk for a severe course of COVID-19. Treatment acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with anti-SARS-CoV-2 monoclonal antibodies (mAbs) has become widely accepted. However, the effects mAb treatment on long-term primary cellular response to SARS-CoV-2 unknown. In following study, we investigated immune responses Spike S1, Membrane (M) and Nucleocapsid (N) antigens using ELISpot assay in unvaccinated, mAb-treated...
Background Herpes simplex viruses (HSV) cause ubiquitous human infections. For vaccine development, knowledge concerning correlates of protection is essential. Therefore, we investigated (I) if humans are in principle capable producing cell-to-cell spread inhibiting antibodies against HSV and (II) whether this capacity associated with a reduced HSV-1 reactivation risk. Methods We established high-throughput HSV-1-ΔgE-GFP reporter virus-based assay evaluated 2,496 plasma samples for...
The emergence of SARS-CoV-2 in 2019 led to a global pandemic with significant impact on healthcare systems. Healthcare workers were particularly vulnerable due frequent contact COVID-19 patients. Despite vaccination, they remained at higher risk as the vaccines provided limited protection against infection viral variants, like Delta or Omicron BA.1 and BA.5. Three years after onset pandemic, we evaluated frequencies among varying levels patient contact: high-risk (frequent contact),...
Abstract Background When patients with chronic kidney disease are infected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) they can face two specific problems: Virus-specific immune responses may be impaired and remdesivir, an antiviral drug described to shorten the time recovery, is contraindicated. Antiviral treatment convalescent plasma could alternative option. Methods In this case series we present transplant recipients dependent on haemodialysis who were SARS-CoV-2...